Shares of Arrowhead Pharmaceuticals (ARWR) surged 12.25% in intraday trading on Wednesday, driven by a combination of positive analyst sentiment and a significant financial milestone. The stock's impressive rally comes amid renewed investor optimism about the company's growth prospects and financial position.

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals, maintaining an $80 price target. This bullish stance highlights the company's potential for growth, particularly emphasizing its pivotal siRNA program and expanding pipeline. The analyst's vote of confidence has likely contributed to the increased investor interest, as the price target suggests substantial upside from current trading levels.

Adding to the positive momentum, Arrowhead Pharmaceuticals announced a significant financial transaction with Sarepta Therapeutics. The company revealed it has redeemed approximately $50 million of Arrowhead stock and will receive about $50 million in cash as satisfaction of a milestone from Sarepta. This development not only strengthens Arrowhead's balance sheet but also validates the progress in its partnership with Sarepta, further boosting investor confidence in the company's strategic direction and pipeline potential.